News & Updates

Long-term oral progestogen therapy effective, well tolerated in endometriosis management
Long-term oral progestogen therapy effective, well tolerated in endometriosis management
19 Mar 2025 byDr. Tak-Keung Sum, Specialist in Obstetrics and Gynaecology, Private practice, Hong Kong

Endometriosis is a chronic disease, which requires interventions that are both effective and well tolerated in the long term. Dr Tak-Keung Sum, Specialist in Obstetrics and Gynaecology in private practice in Hong Kong, reviews clinical and real-world evidence on the long-term efficacy and safety of an oral progestogen, dienogest (Visanne®, Bayer), and shares his personal experience in managing endometriosis across different patient profiles.

Long-term oral progestogen therapy effective, well tolerated in endometriosis management
19 Mar 2025
Molecular detection of EGFR exon20ins in NSCLC: Why, when and how?
Molecular detection of EGFR exon20ins in NSCLC: Why, when and how?
14 Mar 2025 byDr. Molly Li, Department of Clinical Oncology, Chinese University of Hong Kong; Prof. Yoon-La Choi, Samsung Medical Center, Sungkyunkwan University School of Medicine, South Korea

Genome-guided therapy has improved survival outcomes and reduced toxicities and complications from cytotoxic chemotherapy, thereby enhancing the quality of life of patients with non-small-cell lung cancer (NSCLC). At an industry-sponsored symposium, Dr Molly Li of the Department of Clinical Oncology, the Chinese University of Hong Kong, and Professor Yoon-La Choi of the Samsung Medical Center, Sungkyunkwan University School of Medicine, South Korea, focused on the clinical importance and challenges of detecting EGFR exon 20 insertions (exon20ins) in NSCLC patients and discussed the latest clinical evidence on EGFR exon20ins–targeted treatments.

Molecular detection of EGFR exon20ins in NSCLC: Why, when and how?
14 Mar 2025
CKD management in primary care: Why use SGLT2i?
CKD management in primary care: Why use SGLT2i?
25 Feb 2025 byDr. Catherine Xiao-Rui Chen, Department of Family Medicine and Primary Healthcare, Kowloon Central Cluster, Hospital Authority; Prof. Per-Henrik Groop, University of Helsinki, Finland; Dr. Maggie Ma, Combined Renal Replacement Services, Queen Mary Hospital; Dr. Ting-Bong Chan, Jockey Club School of Public Health and Primary Care, Chinese University of Hong Kong

Primary care physicians, as patients’ first point of contact, play an important role in early detection and timely management of chronic kidney disease (CKD). Sodium-glucose cotransporter-2 inhibitors’ (SGLT2i) positive data in CKD trials have established their role as first-line therapy recommended by international and Hong Kong guidelines. At an industry-sponsored symposium organized by the Hong Kong College of Family Physicians, experts reviewed empagliflozin’s benefits in broad populations of CKD patients, and discussed how its early initiation may slow CKD progression and delay dialysis. Case reports were presented to illustrate real-world benefits of empagliflozin among patients managed in primary care in Hong Kong.

CKD management in primary care: Why use SGLT2i?
25 Feb 2025